We are delighted to welcome new members to our panel of clinical advisers.
Welcome to Dr Ayodeji Adegunsoye, Dr Melissa Lesko, Prof. Jeff Swigris and Dr Melissa Wickremasinghe.
Looking forward to great discussions!
https://t.co/Az3ZZXDWMc
@SwigOutFishing@drdayjee@mwickremas
Our poster on feasibility of home spirometry in ILD is in Hall 7 right now. The study led by Dr @mwickremas, had high patient adherence & acceptability with home spirometry & oximetry on 91% of study days #ERSCongress#ERS2022
Given sensitivity of frequent spirometry in predicting progression of ILDs home spirometry is a realistic and highly valuable alternative to clinic assessment @mwickremas#ERS2022#ERSCongress2022
Today we announce our IPF Scientific Advisory Board with leading global experts to help us implement our platform technology with a growing number of biopharma partners worldwide @TobyMMaher@drphilmol Paul Ford, Bill Bradford and Mel Wickremasinghe.
https://t.co/n3uT5h8ECg
<2 weeks until ERS 2022 - so much to look forward to:
New pMp data from the #ILD study with lead @mwickremas
Poster from @wlinng at partner site @Beaumont_Dublin on remote early detection of CT-ILD progression
Plus new #ILD collaborations
See you at stand J.03A in Barcelona!
Exciting news! Ethics committee review of our planned clinical trial assessing health economics of remote monitoring in ILD with PI @mwickremas has commenced. Fingers crossed for good news! Full update here . #IPF https://t.co/ee9ojYPnTZ
Big thanks to all the attendees at our @DHealthLDN showcase today. In particular we'd like to thank Kay Boycott our chair, Our fantastic clinician speakers Laura Lowndes & @mwickremas and our inspirational patient speaker @TriathARon#DigitalHealthLondonTurns5
COVID-19 has accelerated adoption of digital tech in healthcare & lifescience, opening up new possibilities for patients. Discussing how we can seize the opportunity with @JR_MerseyCare @tara_donnelly1
@EI_TheUK @patientMpower@Deciphex
Serosep
@Mirai_Medical#irelanduktrade
50% OF UK IPF PATIENTS ARE DENIED ACCESS TO ANTIFIBROTIC TREATMENT BY NICE RULES. Early stage IPF patients (FVC > 80%) and those with advanced symptoms (FVC>50%) cannot be prescribed. This is grossly unfair and results in worse outcomes and ultimately shorter lives
@DrDevChauhan@LukeOShea1@uclh @drcolinmitchell It’s great for patients to interact with their e health record, the #CIE is our @ImperialNHS NWL patient portal - it allows patients to add remote data, see all their results/letters and share their record with anyone they choose @idiopathic
There are 70,000 people living with ILD in the UK. It is unclear whether government guidance on extreme vulnerability and shielding covers ILD patients. As yet, very few patients have been contacted by either the NHS or their GP.
Chief Medical Officers : UK Interstitial Lung Disease (ILD) patients need to know URGENTLY if we are considered ‘extremely vulnerable’ to Covid-19 and must follow shielding guidance. PLEASE CLARIFY
@CMO_England @CMOWales @cathcalderwood1 @PHE_uk @RCPLondon@ActionPFcharity